Abstract: Biomedical engineering innovations towards the reconstruction of biological functions seek to improve the quality of patients' lives. The coordinated research project "RESPONSE -Partnership for Innovation in Implant Technology" (BMBF program Twenty20 -Partnership for Innovation, 2014 -2021) is focusing on the development of novel concepts for (i) cardiovascular scaffolds, glaucoma and ENT stents, (ii) transcatheter heart valves and venous valves, (iii) polymeric implants and polymer/drug formulations. Current clinical paradigm shifts, fostered by the progress in implant technology and a growing global demand, frame the background for the joint research efforts of academia and industry in the RESPONSE consortium.
Introduction
Originating from bare-metal intravascular stent technology of the 1990s, a growing number stent-based therapeutic concepts is currently proliferating into various medical fields [1] . Beyond the cardiovascular application in coronary and peripheral vessels, stents have found their way for instance into gastroenterology, urology and ophthalmology. Furthermore, they are being considered in gynecology and otolaryngology. Quite prominently, stents represent the enabling platform technology for the highly successful field of percutaneous heart valves, which have made transcatheter aortic valve implantation (TAVI) available specifically to mostly elderly and otherwise inoperable patients.
A seemingly perpetual research demand in these fields aims at ever higher device efficacy and safety, as well as ever less invasive application technologies in order to provide therapeutic options for growing patient cohorts, and to extend the range of applications. In this context, the project consortium RESPONSE is pursuing the following key concepts for novel implant platforms, see also 
Cardiovascular implants
Driven by a high clinical demand, bioabsorbable drug-eluting scaffolds are being developed for coronary and peripheral application (see Figure 2 , left). New structural scaffold designs, polymeric material formulations, magnesium alloys and process technologies are being investigated in order to overcome limitations of existing devices [2] [3] [4] [5] . Furthermore, scaffold coatings with responsive drug release shall allow for an adaptive implant/tissue interaction in order to improve clinical outcome [6, 7] .
Electrospinning is being established as an innovative manufacturing technology for the fabrication of artificial, polymer-based leaflet structures (Figure 2 , right) for surgical heart valve prostheses and TAVI [8] . Technology spill-over from TAVI is aspired using surface functionalized polymeric nanofiber nonwovens for the development of transcatheter deep venous valves to accomplish a device-based therapeutic option for chronic venous insufficiency. Here emphasis is put on physiological adaptiveness and clinical feasibility.
For the broad field of cardiac rhythm management, high endurance insulation polymers for stimulation electrodes are investigated. Responsive anti-infective lead coatings and protective coating systems for the prevention of tissue adhesion are designed based on a detailed mapping of neointimal fibrotic lead encapsulation [9] .
Ophthalmologic implants
Glaucoma and cataract, as two predominant eye diseases, have been identified to be approached by significant device innovations. In this context, adaptive implant-based concepts for minimal invasive glaucoma treatment are developed (Figure 3, left) . Pressure-controlled drainage of aqueous fluid is achieved through micro valves, and implant healing is augmented by local drug delivery [10] .
Primary open-angle glaucoma shall be addressed by next generation drug delivery systems with long-term in vivo drug release (Figure 3, right) . The systems comprise in situ polymerizing drug carriers, and will be applied by minimal invasive injection systems [11] . In parallel, in-depth understanding of fibrotic processes and drug distribution mechanisms is gained through extensive in vitro and ex vivo experimentation [12] [13] [14] . Restoration of near and far vision in cataract patients, or as an elective procedure in presbyopes, shall be achieved through reconstruction of the enucleated capsular bag. A flexible and swellable pre-formed polymer implant is being developed as part of a modified lens refilling approach. Next to drug selection for the prevention of secondary cataract, microsurgical implantation techniques are being developed, and biomechanics of lens accommodation is studied [15] .
Otolaryngologic implants
Stent-based therapeutic perspectives are evaluated for chronic middle ear ventilation disorders (Figure 4, left) . Here, a permanent stent or temporary scaffold shall be applied for the restoration of the physiological venting function of the Eustashian tube, mediated by anti-inflammatory and antiinfective local drug release [16] .
Quality of hearing and long-term efficacy of inner ear implants is addressed by efforts towards optimization of the implant/tissue interface. Here, polymer/drug coatings (Figure 4 , right) are used in combination with surface topology modulation [17] . Device-based innovations in medicine hold far-reaching future potentials for health care regarding the enhancement of patients' quality of life, as well as for economic value creation. The consortium RESPONSE integrates stakeholders along the entire translational pathway of medical devices and is determined to contribute to an acceleration of innovation processes in the fields of cardiovascular, ophthalmologic and otolaryngologic implants. These areas of high epidemiological prevalence exhibit particular demands for technologydriven innovation, in combination with high market volumes and growth rates. In Germany, an annual cohort of 800,000 patients with coronary or structural heart disease or stroke is being addressed, as well as 440,000 patients with cataract or glaucoma, and 14 million relevant people with hearing disorders. 
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